Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptors (GLP-1Rs) have been found in the brain, but whether GLP-1R agonists (GLP-1RAs) influence brain glucose metabolism is currently unknown. The study aim was to evaluate the effects of a single injection of the GLP-1RA exenatide on cerebral and peripheral glucose metabolism in response to a glucose load. In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT). The cerebral glucose metabolic rate (CMRglu) was measured by positron emission tomography after an injection of [18F]2-fluoro-2-deoxy-d-glucose before the OGTT, and the rate of glucose absorption (RaO) and disposal was assessed using stable isotope tracers. Exenatide reduced RaO0–60 min (4.6 ± 1.4 vs. 13.1 ± 1.7 μmol/min ⋅ kg) and decreased the rise in mean glucose0–60 min (107 ± 6 vs. 138 ± 8 mg/dL) and insulin0–60 min (17.3 ± 3.1 vs. 24.7 ± 3.8 mU/L). Exenatide increased CMRglu in areas of the brain related to glucose homeostasis, appetite, and food reward, despite lower plasma insulin concentrations, but reduced glucose uptake in the hypothalamus. Decreased RaO0–60 min after exenatide was inversely correlated to CMRglu. In conclusion, these results demonstrate, for the first time in man, a major effect of a GLP-1RA on regulation of brain glucose metabolism in the absorptive state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 6×
“The group included 10 with impaired fasting glucose/impaired glucose tolerance (IGT), 2 with IGT, and 3 with newly discovered T2DM during the screening OGTT.”
BackgroundInfluentialHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“Although GLP-1 and some GLP-1R agonists (GLP-1RAs) can cross the blood-brain barrier (9,10), their effects on the CNS are poorly understood.”
BackgroundInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · cited 5×
“The group included 10 with impaired fasting glucose/impaired glucose tolerance (IGT), 2 with IGT, and 3 with newly discovered T2DM during the screening OGTT.”
BackgroundInfluentialMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 4×
“We have shown that native GLP-1, secreted in response to a meal, potentiates insulin secretion and glucose sensing (7) and inhibits hepatic glucose production without altering peripheral glucose disposal (8).”
BackgroundMethodInfluentialSelf-citationEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · cited 2×
“The brain receives multiple inputs including 1) hormones, such as leptin, ghrelin, peptide YY (PYY), glucagon like peptide-1 (GLP-1), and insulin, 2) nutrient-related signals that regulate fat accumulation in adipose tissue and hepatic and peripheral glucose metabolism, and 3) signals from the gastrointestinal tract t…”
BackgroundDirect effect of GLP-1 infusion on endogenous glucose production in humans
Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143 · cited 1×
“We have shown that native GLP-1, secreted in response to a meal, potentiates insulin secretion and glucose sensing (7) and inhibits hepatic glucose production without altering peripheral glucose disposal (8).”
BackgroundSelf-citationGLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Research works printed but not linked: 12
- Alvarez, 2005, The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem, J Neurochem, 92, 798, 10.1111/j.1471-4159.2004.02914.x · DOI · Paper page
- Schlögl, 2013, Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity, Diabetes Care, 36, 1933, 10.2337/dc12-1925 · DOI · Paper page
- Lerche, 2008, Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans, Diabetes, 57, 325, 10.2337/db07-1162 · DOI · Paper page
- Gejl, 2012, Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia, J Cereb Blood Flow Metab, 32, 2146, 10.1038/jcbfm.2012.118 · DOI · Paper page
- Sisley, 2014, Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect, J Clin Invest, 124, 2456, 10.1172/JCI72434 · DOI · Paper page
- Matsuda, 1999, Altered hypothalamic function in response to glucose ingestion in obese humans, Diabetes, 48, 1801, 10.2337/diabetes.48.9.1801 · DOI · Paper page
- Navarro, 1996, Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake, J Neurochem, 67, 1982, 10.1046/j.1471-4159.1996.67051982.x · DOI · Paper page
- Yang, 2004, Metabolic pathways that mediate inhibition of hypothalamic neurons by glucose, Diabetes, 53, 67, 10.2337/diabetes.53.1.67 · DOI
- Hussain, 2015, Glucokinase activity in the arcuate nucleus regulates glucose intake, J Clin Invest, 10.1172/JCI77172 · DOI
- Banks, 2012, Insulin in the brain: there and back again, Pharmacol Ther, 136, 82, 10.1016/j.pharmthera.2012.07.006 · DOI · Paper page
- Hasselbalch, 1999, No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans, Diabetes, 48, 1915, 10.2337/diabetes.48.10.1915 · DOI · Paper page
- Bingham, 2002, The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study, Diabetes, 51, 3384, 10.2337/diabetes.51.12.3384 · DOI · Paper page
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationBurmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
“5 hours, as described.((26)) During the first 60 minutes, a dynamic scan was obtained to image the heart, the liver and abdominal subcutaneous tissue (34 frames, 12 3 120, 6 3 180, 5 3 300, 4 3 600, 6 3 1,800, and 1 3 600 seconds; Fig.”
BackgroundMethodSelf-citationGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
“GLP-1 also has other pleiotropic effects (Figure 1), including delay in gastric emptying and glucose absorption [24,25], stimulation of brain areas involved in the regulation of glucose homeostasis and food reward [26], suppression of glucagon secretion [25], beneficial effects on cardiovascular risk factors, a natriu…”
BackgroundSelf-citationHemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204.pub2 · Cited by 63
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
“35 Thus, some of the metabolic effects observed here might be related to the cross-talk between gut and brain, not only through the well known anorexigenic effects,(36) but also through the modulation of gastric absorption.(35) Furthermore, liraglutide has been shown to change the composition of gut microbiota,(37) wh…”
BackgroundSelf-citationWang, Y., Wang, J., Gong, Q., Wu, H., Yang, S., He, J., Hu, X., & Huang, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0384 · Cited by 18
Metadata
- Authors
- Daniele, G., Iozzo, P., Molina-Carrion, M., Lancaster, J., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., & Gastaldelli, A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-06-26
- Volume
- 64
- Issue
- 10
- Pages
- 3406-3412
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1848685510
- Cited by
- 62
- References
- 8
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Amylin Pharmaceuticals, Bristol-Myers Squibb, and AstraZeneca
- Consiglio Nazionale delle Ricerche (CNR Ageing project)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.